THREATS CONTINUALLY EMERGE AND EVOLVE

Novavax creates innovative vaccines that address some of the world’s most pressing infectious diseases.

Our Approach

Our scientists are committed to developing vaccine candidates for some of the world’s toughest viral threats by utilizing the power of our innovative recombinant nanoparticle vaccine platform.

Our Science

Our vaccine technology combines the power and speed of genetic engineering with the immunogenicity enhancing properties of our Matrix-M™ adjuvant to efficiently produce highly immunogenic particles targeting some of the most pressing viral infectious diseases.

Our Technology

We are committed to delivering novel products that leverage our innovative proprietary recombinant nanoparticle vaccine technology to prevent a broad range of infectious diseases.

Our saponin-based Matrix-M™ adjuvant enhances the immune response and has a dose-sparing effect, both of which are critical to successful vaccine development.

Our pipeline is more important than ever

Novavax has demonstrated its ability to quickly produce viable, promising vaccine candidates for emerging infectious diseases.

Areas of Research

COVID-19

COVID-19

At the end of 2019, a novel coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei Province of China. The severity and rapid spread of COVID-19 (caused by SARS-CoV-2), resulted in a global pandemic declared by the World Health Organization in March 2020. The virus has spread to more than 100 countries, including the United States. Researchers have confirmed that the virus has spread via human-to-human transmission. Full-genome sequencing and phylogenic analysis indicated that the coronavirus that causes COVID-19 is a beta coronavirus in the same subgenus as the severe acute respiratory syndrome (SARS) virus (as well as several bat coronaviruses), but in a different clade. The structure of the receptor-binding gene region is very similar to that of the SARS coronavirus, and the virus has been shown to use the same receptor, the angiotensin-converting enzyme 2 (ACE2), for cell entry. The Middle East respiratory syndrome (MERS) virus, another beta coronavirus, appears more distantly related. It appears likely that bats may be the primary source of the coronavirus that causes COVID-19 as its RNA sequence is most similar to that of 2 bat coronaviruses. A safe and effective vaccine may be the best way to prevent SARS-CoV-2 transmission and infection. To date, no vaccine has been approved by the FDA, but a range of vaccine candidates are under development.

Seasonal influenza

Seasonal influenza

Seasonal influenza is a worldwide infectious disease that occurs in the general population, but with serious illness generally occurring in more susceptible populations such as children under 18 years of age and older adults. A 2018 study by the Centers for Disease Control and Prevention (CDC), published in Clinical Infectious Diseases, suggested that, on average, about 8% of the US population gets sick from the flu each season, with that percentage ranging from 3% to 11% depending on the season. The seasonal influenza vaccine market was $3.96 billion globally in 2018 and is projected to be $6.20 billion in 2020 as recent flu seasons have shown an increase in the seasonal influenza disease burden. For the 2019 to 2020 flu season, the CDC estimated that by April 2020, seasonal influenza in the United States will have resulted in 39 to 56 million illnesses, 410,000 to 740,000 hospitalizations, and 24,000 to 62,000 deaths, which will be a dramatic increase across all categories compared to previous years.

Respiratory syncytial virus (RSV)

Respiratory syncytial virus (RSV)

Currently, there is no approved RSV vaccine available to combat the estimated 64 million RSV infections that occur globally each year. We have identified three susceptible target populations that we believe could benefit from the development of our respiratory syncytial virus fusion (F) protein nanoparticle vaccine candidate (RSV F vaccine) in different formulations: infants via maternal immunization, adults aged 60 years and older, and children aged 6 months to 5 years. We have developed and conducted Phase 3 trials for vaccine candidates for 2 of those target populations: infants via maternal immunization and adults aged 60 years and older. We continue to assess the development opportunities for our RSV F vaccine for pediatric patients. With our current estimates of the annual global cost burden (direct and indirect costs) of RSV in excess of $88 billion, we believe our RSV F vaccine represents a multibillion-dollar worldwide opportunity.